United Theranostics is a cancer-care organization focused on molecular imaging and precision radiopharmaceutical therapy. Its approach recognizes that each person’s needs are different, combining advanced analytics and clinical evidence with individual biology, preferences, and values to develop tailored treatment plans. The organization’s Center of Excellence clinics provide outpatient care in a supportive setting, while its teams collaborate with patients’ oncologists, urologists, and other referring providers.

Theranostics combines diagnostic imaging and treatment: PET scans help visualize tumors, SPECT scans monitor the effects of therapy, and radiopharmaceuticals target cancer. United Theranostics offers services for prostate cancer, metastatic neuroendocrine cancer, and thyroid cancer. Treatments include Pluvicto and Xofigo for prostate cancer, Lutathera for neuroendocrine tumors, and radioiodine for thyroid cancer. Imaging services include quantitative SPECT/CT, dosimetry, PET/CT, CT, and SPECT/CT.

The organization also supports clinical trials and research partnerships to expand access to emerging radiopharmaceutical therapies and precision-medicine options. Its locations include clinics in Maryland, New Jersey, New Mexico, California, Illinois, and Florida.